311 related articles for article (PubMed ID: 31428520)
1. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1
Mohan N; Hosain S; Zhao J; Shen Y; Luo X; Jiang J; Endo Y; Wu WJ
Oncoimmunology; 2019; 8(9):e1624128. PubMed ID: 31428520
[TBL] [Abstract][Full Text] [Related]
2. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer.
Liu WL; Zhang YQ; Luo XJ; Zhu YY; Song L; Ming ZH; Zhang LX; Li MJ; Lv RC; Zhang GJ; Chen M
Int J Nanomedicine; 2023; 18():5141-5157. PubMed ID: 37705867
[TBL] [Abstract][Full Text] [Related]
3. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.
Pan MR; Wu CC; Kan JY; Li QL; Chang SJ; Wu CC; Li CL; Ou-Yang F; Hou MF; Yip HK; Luo CW
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31905966
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab for the treatment of triple-negative breast cancer.
Heimes AS; Schmidt M
Expert Opin Investig Drugs; 2019 Jan; 28(1):1-5. PubMed ID: 30474425
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer.
Saleh R; Taha RZ; Sasidharan Nair V; Alajez NM; Elkord E
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31349612
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
García-Teijido P; Cabal ML; Fernández IP; Pérez YF
Clin Med Insights Oncol; 2016; 10(Suppl 1):31-9. PubMed ID: 27081325
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
Saleh R; Toor SM; Khalaf S; Elkord E
Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
[No Abstract] [Full Text] [Related]
9. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.
Kagihara JA; Andress M; Diamond JR
Expert Rev Precis Med Drug Dev; 2020; 5(2):59-65. PubMed ID: 32190733
[TBL] [Abstract][Full Text] [Related]
11. Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer.
Brasó-Maristany F; Sansó M; Chic N; Martínez D; González-Farré B; Sanfeliu E; Ghiglione L; Carcelero E; Garcia-Corbacho J; Sánchez M; Soy D; Jares P; Peg V; Saura C; Muñoz M; Prat A; Vivancos A
Front Oncol; 2021; 11():710596. PubMed ID: 34616675
[TBL] [Abstract][Full Text] [Related]
12. De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients.
Ou-Yang F; Li CL; Chen CC; Shen YC; Moi SH; Luo CW; Xia WY; Wang YN; Lee HH; Wang LH; Wang SC; Pan MR; Hou MF; Hung MC
Am J Cancer Res; 2022; 12(1):123-137. PubMed ID: 35141008
[TBL] [Abstract][Full Text] [Related]
13. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
[TBL] [Abstract][Full Text] [Related]
14. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
15. Combination of FAK inhibitor and cytokine-induced killer cell therapy: An alternative therapeutic strategy for patients with triple-negative breast cancer.
Wu CC; Pan MR; Shih SL; Shiau JP; Wu CC; Chang SJ; Kao CN; Chen FM; Hou MF; Luo CW
Biomed Pharmacother; 2023 Jul; 163():114732. PubMed ID: 37254289
[TBL] [Abstract][Full Text] [Related]
16. The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer.
Li J; Zhang D; Liu Z; Wang Y; Li X; Wang Z; Liang G; Yuan X; Li Y; Komorowski AL; Rozen WM; Orlandi A; Takabe K; Franceschini G; Jerusalem G; Wang X
Ann Transl Med; 2023 Jan; 11(2):83. PubMed ID: 36819490
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
18. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L
Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]